BDBM330041 (4R,12aS)-N-(1-(2,4-difluorophenyl)cyclopropyl)-7-hydroxy-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-[1,3]oxazino[3,2-d]pyrido[1,2-a]pyrazine-9-carboxamide::US10689399, Compound 5::US9663528, 5
SMILES: C[C@@H]1CCO[C@H]2Cn3cc(C(=O)NC4(CC4)c4ccc(F)cc4F)c(=O)c(O)c3C(=O)N12
InChI Key: InChIKey=LRWVNSNSOHQKNO-BZNIZROVSA-N
Data: 2 IC50
Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kcal/mole | IC50 nM | Kd nM | EC50/IC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
POU domain, class 2, transcription factor 2 (Homo sapiens (Human)) | BDBM330041 ( (4R,12aS)-N-(1-(2,4-difluorophenyl)cyclopropyl)-7...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 2.23E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Gilead Sciences, Inc. US Patent | Assay Description The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an... | US Patent US10689399 (2020) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Solute carrier family 22 member 2 (Homo sapiens (Human)) | BDBM330041 ( (4R,12aS)-N-(1-(2,4-difluorophenyl)cyclopropyl)-7...) | Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 2.23E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Gilead Sciences, Inc. US Patent | Assay Description The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an... | US Patent US9663528 (2017) BindingDB Entry DOI: 10.7270/Q24F1SVF | |||||||||||
More data for this Ligand-Target Pair |